Early Asset Development
Defining a winning Target Product Profile (TPP) for early-stage haemophilia asset.
The Client and Challenges
A pharmaceutical company sought to define a clear strategic direction for a pre-clinical haemophilia A asset. The key challenge was aligning internal stakeholders around a TPP and the optimal indication to pursue, in order to maximise future value in a competitive, evolving treatment landscape.
The Osprey Approach
Assessed potential indications, current and future standards of care, and identified the value a new product would need to deliver in each. Through prioritisation and a collaborative workshop, the team explored key uncertainties and defined the opportunity space, refining the TPP for the most promising indication based on value and commercial potential.
Output and Impact
Aligned the client team around an evidence-based TPP and identified the most commercially attractive indication to pursue. Provided a robust framework for early asset development decisions, and identified that pursuing a novel route of administration would add significant value, supporting optimisation of future portfolio value.
